Pfizer Inc.

Stocks

Market Closed - NYSE Other stock markets 21:02:46 15/07/2026 BST			5-day change	1st Jan Change
24.82 ^USD	+2.35%		+3.20%	-0.32%

07-15	Celcuity shares fall as launch delay eclipses US approval for breast cancer drug	RE
07-15	Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval	RE

Published on 06/03/2026 at 08:20 pm BST - Modified on 06/03/2026 at 10:05 pm BST

S&P Capital IQ

Presenter Speech
Richard Handler (Analysts)

Okay, everybody. It is my treat. I'm Rich Handler, CEO of Jefferies. I get the pleasure of interviewing my good friend, Albert Bourla, CEO of Pfizer.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

07-15	Celcuity shares fall as launch delay eclipses US approval for breast cancer drug	RE
07-15	Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval	RE
07-14	US FDA approves Celcuity's breast cancer drug	RE
07-13	BMO Capital Adjusts Price Target on Pfizer to $30 From $34, Maintains Outperform Rating	MT
07-13	Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug	MT
07-10	Health Care Down on Rotation Back to Tech - Health Care Roundup	DJ
07-10	Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA	DJ
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	Pfizer Poised for Mixed Second Quarter, RBC Says	MT
07-10	Pfizer Inc. and Astellas Pharma Inc. Receive U.S. FDA Approval for PADCEV Plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer	CI
07-10	BofA Securities Adjusts Pfizer Price Target to $26 From $27	MT
07-10	PFIZER INC : RBC reiterates its Neutral rating	ZD
07-10	Pfizer Seen Reporting Q2 Revenue In Line With Consensus, EPS Below Estimates, RBC Says	MT
07-10	Polish air traffic control faces funding freeze over COVID vaccine ruling	RE
07-10	Pfizer's Vaccine Disputes With Poland, Romania Continue	MT